U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Adenoid Cystic Carcinoma

MedGen UID:
1779973
•Concept ID:
C5446668
•
Neoplastic Process

Definition

Adenoid cystic carcinoma that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Adenoid Cystic Carcinoma

Recent clinical studies

Etiology

Effectiveness and tolerance of electrochemotherapy as palliative therapy for patients with head and neck cancer and malignant melanoma and its relation to early skin reaction.
Caballero-Borrego M, Coll S, Navarrete P
Braz J Otorhinolaryngol 2024 Jan-Feb;90(1):101365. Epub 2023 Nov 22 doi: 10.1016/j.bjorl.2023.101365. PMID: 38006727Free PMC Article
MYB-QKI rearrangement in angiocentric glioma.
Lian F, Wang LM, Qi XL, Liu LN, Wang XF, Fu J, Xiong J, Lu DH, Piao YS
Clin Neuropathol 2020 Nov/Dec;39(6):263-270. doi: 10.5414/NP301284. PMID: 32589128
A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors.
Ferrarotto R, Eckhardt G, Patnaik A, LoRusso P, Faoro L, Heymach JV, Kapoun AM, Xu L, Munster P
Ann Oncol 2018 Jul 1;29(7):1561-1568. doi: 10.1093/annonc/mdy171. PMID: 29726923
Efficacy of nelfinavir as monotherapy in refractory adenoid cystic carcinoma: Results of a phase II clinical trial.
Hoover AC, Milhem MM, Anderson CM, Sun W, Smith BJ, Hoffman HT, Buatti JM
Head Neck 2015 May;37(5):722-6. Epub 2014 Jun 18 doi: 10.1002/hed.23664. PMID: 24596143Free PMC Article
Photodynamic therapy of head and neck cancers.
Biel MA
Methods Mol Biol 2010;635:281-93. doi: 10.1007/978-1-60761-697-9_18. PMID: 20552353

Diagnosis

A Rare Case of Primary Pulmonary Adenoid Cystic Carcinoma and the Diagnostic Challenges on Cytology.
White K, Askeland R, Bohy K
S D Med 2021 Jul;74(7):329-331. PMID: 34449997
MYB-QKI rearrangement in angiocentric glioma.
Lian F, Wang LM, Qi XL, Liu LN, Wang XF, Fu J, Xiong J, Lu DH, Piao YS
Clin Neuropathol 2020 Nov/Dec;39(6):263-270. doi: 10.5414/NP301284. PMID: 32589128
Refractory Facial Paralysis: A Case Report.
Hsu YW, Lee JT, Liao YS, Nieh S, Cheng CA, Tsai CK
Acta Neurol Taiwan 2017 Jun 15;26(2):68-71. PMID: 29250758
Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.
Ferrarotto R, Mitani Y, Diao L, Guijarro I, Wang J, Zweidler-McKay P, Bell D, William WN Jr, Glisson BS, Wick MJ, Kapoun AM, Patnaik A, Eckhardt G, Munster P, Faoro L, Dupont J, Lee JJ, Futreal A, El-Naggar AK, Heymach JV
J Clin Oncol 2017 Jan 20;35(3):352-360. Epub 2016 Nov 21 doi: 10.1200/JCO.2016.67.5264. PMID: 27870570Free PMC Article
Adenoid cystic carcinoma manifesting as maxillary jaw pain refractory to conventional treatment: a case report.
Closmann JJ, Schmidt BL
Gen Dent 2006 May-Jun;54(3):195-7. PMID: 16776413

Therapy

Effectiveness and tolerance of electrochemotherapy as palliative therapy for patients with head and neck cancer and malignant melanoma and its relation to early skin reaction.
Caballero-Borrego M, Coll S, Navarrete P
Braz J Otorhinolaryngol 2024 Jan-Feb;90(1):101365. Epub 2023 Nov 22 doi: 10.1016/j.bjorl.2023.101365. PMID: 38006727Free PMC Article
Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors.
Vieito M, Moreno V, Spreafico A, Brana I, Wang JS, Preis M, Hernández T, Genta S, Hansen AR, Doger B, Galvao V, Lenox L, Brown RJ, Kalota A, Mehta J, Pastore F, Patel B, Mistry P, Gu J, Lauring J, Patel MR
Clin Cancer Res 2023 Sep 15;29(18):3592-3602. doi: 10.1158/1078-0432.CCR-23-0092. PMID: 37491846
A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors.
Silk AW, Saraiya B, Groisberg R, Chan N, Spencer K, Girda E, Shih W, Palmeri M, Saunders T, Berman RM, Coric V, Chen S, Zloza A, Vieth J, Mehnert JM, Malhotra J
Eur J Med Res 2022 Jul 2;27(1):107. doi: 10.1186/s40001-022-00732-w. PMID: 35780243Free PMC Article
Treatment response to eribulin and anlotinib in lung metastases from rare perianal adenoid cystic carcinoma: a case report.
Zheng S, Li H, Lin Y, Xie Y, Yin Z, Ge W, Yu T
Anticancer Drugs 2022 Jan 1;33(1):e548-e554. doi: 10.1097/CAD.0000000000001171. PMID: 34321419Free PMC Article
Photodynamic therapy of head and neck cancers.
Biel MA
Methods Mol Biol 2010;635:281-93. doi: 10.1007/978-1-60761-697-9_18. PMID: 20552353

Prognosis

AL101, a gamma-secretase inhibitor, has potent antitumor activity against adenoid cystic carcinoma with activated NOTCH signaling.
Ferrarotto R, Mishra V, Herz E, Yaacov A, Solomon O, Rauch R, Mondshine A, Motin M, Leibovich-Rivkin T, Davis M, Kaye J, Weber CR, Shen L, Pearson AT, Rosenberg AJ, Chen X, Singh A, Aster JC, Agrawal N, Izumchenko E
Cell Death Dis 2022 Aug 5;13(8):678. doi: 10.1038/s41419-022-05133-9. PMID: 35931701Free PMC Article
Treatment response to eribulin and anlotinib in lung metastases from rare perianal adenoid cystic carcinoma: a case report.
Zheng S, Li H, Lin Y, Xie Y, Yin Z, Ge W, Yu T
Anticancer Drugs 2022 Jan 1;33(1):e548-e554. doi: 10.1097/CAD.0000000000001171. PMID: 34321419Free PMC Article
Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors.
Tsimberidou AM, Beer PA, Cartwright CA, Haymaker C, Vo HH, Kiany S, Cecil ARL, Dow J, Haque K, Silva FA, Coe L, Berryman H, Bone EA, Nogueras-Gonzalez GM, Vining D, McElwaine-Johnn H, Wistuba II
Clin Cancer Res 2021 Jul 1;27(13):3584-3594. Epub 2021 May 4 doi: 10.1158/1078-0432.CCR-21-0238. PMID: 33947698
Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.
Ferrarotto R, Mitani Y, Diao L, Guijarro I, Wang J, Zweidler-McKay P, Bell D, William WN Jr, Glisson BS, Wick MJ, Kapoun AM, Patnaik A, Eckhardt G, Munster P, Faoro L, Dupont J, Lee JJ, Futreal A, El-Naggar AK, Heymach JV
J Clin Oncol 2017 Jan 20;35(3):352-360. Epub 2016 Nov 21 doi: 10.1200/JCO.2016.67.5264. PMID: 27870570Free PMC Article
Efficacy of nelfinavir as monotherapy in refractory adenoid cystic carcinoma: Results of a phase II clinical trial.
Hoover AC, Milhem MM, Anderson CM, Sun W, Smith BJ, Hoffman HT, Buatti JM
Head Neck 2015 May;37(5):722-6. Epub 2014 Jun 18 doi: 10.1002/hed.23664. PMID: 24596143Free PMC Article

Clinical prediction guides

Effectiveness and tolerance of electrochemotherapy as palliative therapy for patients with head and neck cancer and malignant melanoma and its relation to early skin reaction.
Caballero-Borrego M, Coll S, Navarrete P
Braz J Otorhinolaryngol 2024 Jan-Feb;90(1):101365. Epub 2023 Nov 22 doi: 10.1016/j.bjorl.2023.101365. PMID: 38006727Free PMC Article
A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors.
Silk AW, Saraiya B, Groisberg R, Chan N, Spencer K, Girda E, Shih W, Palmeri M, Saunders T, Berman RM, Coric V, Chen S, Zloza A, Vieth J, Mehnert JM, Malhotra J
Eur J Med Res 2022 Jul 2;27(1):107. doi: 10.1186/s40001-022-00732-w. PMID: 35780243Free PMC Article
Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors.
Tsimberidou AM, Beer PA, Cartwright CA, Haymaker C, Vo HH, Kiany S, Cecil ARL, Dow J, Haque K, Silva FA, Coe L, Berryman H, Bone EA, Nogueras-Gonzalez GM, Vining D, McElwaine-Johnn H, Wistuba II
Clin Cancer Res 2021 Jul 1;27(13):3584-3594. Epub 2021 May 4 doi: 10.1158/1078-0432.CCR-21-0238. PMID: 33947698
MYB-QKI rearrangement in angiocentric glioma.
Lian F, Wang LM, Qi XL, Liu LN, Wang XF, Fu J, Xiong J, Lu DH, Piao YS
Clin Neuropathol 2020 Nov/Dec;39(6):263-270. doi: 10.5414/NP301284. PMID: 32589128
Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.
Ferrarotto R, Mitani Y, Diao L, Guijarro I, Wang J, Zweidler-McKay P, Bell D, William WN Jr, Glisson BS, Wick MJ, Kapoun AM, Patnaik A, Eckhardt G, Munster P, Faoro L, Dupont J, Lee JJ, Futreal A, El-Naggar AK, Heymach JV
J Clin Oncol 2017 Jan 20;35(3):352-360. Epub 2016 Nov 21 doi: 10.1200/JCO.2016.67.5264. PMID: 27870570Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...